Survivin: A molecular biomarker in cancer

Indian Journal of Medical Research

Volumn 142, Issue April, 2015, Pages 389-397

  Jaiswal, Praveen Kumar ^a,b   Goel, Apul ^b   Mittal, Rama Devi ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Cancer; Cancer therapy; Gene polymorphism; Survivin

Indexed keywords

APOPTOSIS INDUCING FACTOR; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 7; CASPASE 9; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SURVIVIN; TRANSCRIPTION FACTOR E2F; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR MARKER;

APOPTOSIS; BREAST CANCER; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CELL DEATH; DIGESTIVE SYSTEM TUMOR; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MOUTH CANCER; NEOPLASM; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; UROGENITAL TRACT TUMOR; CHEMISTRY; CLASSIFICATION; GENE EXPRESSION REGULATION; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; SINGLE NUCLEOTIDE POLYMORPHISM;

APOPTOSIS; BIOMARKERS, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84932160580     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8: 61-70.
2. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007; 12: 1543-68.
3. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004; 64: 7183-90.
4. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581-9.
5. Sah NK, Khan Z, Khan GJ, Bisen PS. Structural, functional and therapeutic biology of survivin. Cancer Lett 2006; 244: 164-71.
6. Altieri DC, Marchisio PC. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 1999; 79: 1327-33.
7. Xu Y, Fang F, Ludewig G, Jones G, Jones D. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 2004; 23: 527-37.
8. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Mad 1997; 3: 917-21.
9. wheatley SP, McNeish IA. Survivin: a protein with dual roles in mitosis and apoptosis. IntRev Cytol 2005; 247: 35-88.
10. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T, et al. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 2004; 314: 902-7.
11. Caldas H, Honsey Le, Altura RA. Survivin 2alpha: a novel survivin splice variant expressed in human malignancies. Mol Cancer 2005; 4: 11.
12. Yamada Y, Kuroiwa T, Nakagawa T, Kajimoto Y, Dohi T, Azuma H, et al. Transcriptional expression of survivin and its splice variants in brain tumors in humans. JNeurosurg 2003; 99: 738-45.
13. Tamm I, want Y, Sausville E, Scudiero DA, vigna N, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas(CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 59: 5315-20.
14. Altieri DC. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 2006; 5: 478-82.
15. Li C, wu Z, Liu M, Pazgier M, Lu W. Chemically synthesized human survivin does not inhibit caspase-3. Protein Sci 2008; 17: 1624-9.
16. Sun C, Nettesheim D, Liu Z, Olejniczak ET. Solution structure of human survivin and its binding interface with Smac/Diablo. Biochemistry 2005; 44: 11-7.
17. Dohi T, Okada K, Xia F, Wilford C, Samuel T, welsh K, et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004; 279: 34087-90.
18. Sensintaffar J, Scott FL, Peach R, Hager JH. XIAP is not required for human tumor cell survival in the absence of an exogenous death signal. BMC Cancer 2010; 10: 11.
19. wang Z, Fukuda S, Pelus LM. Survivin regulates the p53 tumor suppressor gene family. Oncogene 2004; 23: 8146-53.
20. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem 2004; 279: 40511-20.
21. Hoffman H, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277: 3247-57.
22. O'Connor DJ, Lam EW, Griffin S, Zhong S, Leighton LC, Burbidge SA, et al. Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. EMBO J 1995; 14: 6184-92.
23. Hsieh JK, Yap D, O'Connor DJ, Fogal V, Fallis L, Chan F, et al. Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol Cell Biol 2002; 22: 78-93.
24. Mirza A, McGuirk M, Hockenberry TN, wu Q, Ashar H, Black S, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21: 2613-22.
25. Löhr K, Möritz C, Contente A, Dobbelstein M. p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem 2003; 278: 32507-16.
26. Li W, Fan J, Bertino JR. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res 2001; 61: 2579-82.
27. Flatt PM, Tang LJ, Scatena CD, Szak ST, Pietenpol JA. p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Mol Cell Biol 2000; 20: 4210-23.
28. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adults tissues. Mol Cancer Ther 2006; 5: 1087-98.
29. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999; 17: 2100-4.
30. Grabowski P, Kuhnel T, Muhr-wilkenshoff F, Heine B, Stein H, Hopfner M, et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 2003; 88: 115-9.
31. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-34.
32. Nasu S, Yagihashi A, Izawa A, Saito K, Asanuma K, Nakamura M, et al. Survivin mRNA expression in patients with breast cancer. Anticancer Res 2002; 22: 1839-43.
33. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 2001; 92: 271-8.
34. Sarela AI, verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 2002; 86: 886-92.
35. Cohen C, Lohmann CM, Cotsonis G, Lawson D, Santoianni R. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol 2003; 16: 574-83.
36. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am JDermatopathol 2008; 30: 117-22.
37. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000; 46: 645-50.
38. Ikeguchi M, Ueda T, Sakatani T, Hirooka Y, Kaibara N. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol 2002; 11: 33-40.
39. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000; 31: 1080-5.
40. Yu J, Leung WK, Ebert MP, Ng EK, Go MY, wang HB, et al. Increased expression of survivin in gastric cancer patients and in first degree relatives. Br J Cancer 2002; 87: 91-7.
41. Lehner R, Lucia MS, Jarboe EA, Orlicky D, Shroyer AL, McGregor JA, et al. Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morphol 2002; 10: 134-8.
42. Mori A, wada H, Nishimura Y, Okamoto T, Takemoto Y, Kakishita E. Expression of the antiapoptosis gene survivin in human leukemia. Int JHematol 2002; 75: 161-5.
43. Khan Z, Tiwari RP, Mulherkar R, Sah NK, Prasad GB, Shrivastava BR, et al. Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings. Head Neck 2009; 31: 1039-48.
44. Lauxen I, Oliveira MG, Rados P, Lingen M, Nor JF, Sant'ana Filho M. Immunoprofiling of oral squamous cell carcinomas reveals high p63 and survivin expression. Oral Dis 2014; 20: e76-80.
45. Salz W, Eisenberg D, Plescia J, Garlick DS, weiss RM, wu XR, et al. A survivin gene signature predicts aggressive tumor behavior. Cancer Res 2005; 65: 3531-4.
46. Khan Z, Khan N, Tiwari RP, Patro IK, Prasad GB, Bisen PS. Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells. Radiother Oncol2010; 96: 267-73.
47. Khan Z, Bisen PS. Oncoapoptotic signaling and deregulated target genes in cancers: special reference to oral cancer. Biochim Biophys Acta 2013; 1836: 123-45.
48. Sherry ST, ward M, Sirotkin K. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res 1999; 9: 677-9.
49. Perez LO, Abba MC, Dulout FN, Golijow CD. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 2006; 12: 1426-9.
50. Bojesen SE, Nordestgaard BG. The common germline Arg72Pro polymorphism of p53 and increased longevity in humans. Cell Cycle 2008; 7: 158-63.
51. Katkoori VR, Jia X, Shanmugam C, Wan W, Meleth S, Bumpers H, et al. Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res 2009; 15: 2406-16.
52. Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, et al. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 2008; 8: 32.
53. Jaiswal PK, Goel A, Mandhani A, Mittal RD. Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort. Mol Biol Rep 2012; 39: 5615-21.
54. Zahedi P, Aminimoghaddam S, Sayahpour FA, Haghpanah V, Amiri P, Fereidoni F, et al. Association of survivin gene polymorphism with endometrial cancer. Int J Gynecol Cancer 2012; 22: 35-7.
55. Li Y, wang J, Jiang F, Lin W, Meng W. Association of polymorphisms in survivin gene with the risk of hepatocellular carcinoma in Chinese Han population: a case control study. BMC Med Genet 2012; 13: 1.
56. Theodoropoulos GE, Michalopoulos NV, Panoussopoulos SG, Taka S, Gazouli M. Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumor characteristics. Pancreas 2010; 39: 976-80.
57. Lichtenstein P, Holm NV, verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85.
58. Ulybina YM, Kuligina ES, Mitiushkina Nv, Sherina NY, Baholdin DV, Voskresenskiy DA, et al. Distribution of coding apoptotic gene polymorphisms in women with extreme phenotypes of breast cancer predisposition and tolerance. Tumori 2011; 97: 248-51.
59. Boidot R, vegran F, Jacob D, Chevrier S, Gangneux N, Taboureau J, et al. The expression of BIRC5 is correlated with loss of specific chromosomal regions in breast carcinomas. Genes Chromosomes Cancer 2008; 47: 299-308.
60. Kawata N, Tsuchiya N, Horikawa Y, Inoue T, Tsuruta H, Maita S, et al. Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int J Cancer 2011; 129: 1872-80.
61. Wang YH, Chiou HY, Lin CT, Hsieh HY, wu CC, Hsu CD, et al. Association between survivin gene promoter -31C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology 2009; 73: 670-4.
62. Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos FI, Marousi S, et al. The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Cell Oncol 2011; 34: 381-91.
63. Gazouli M, Tzanakis N, Rallis G, Theodoropoulos G, Papaconstantinou I, Kostakis A, et al. Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis 2009; 24: 145-50.
64. Upadhyay R, Khurana R, Kumar S, Ghoshal UC, Mittal B. Role of survivin gene promoter polymorphism (-31G>C) in susceptibility and survival of esophageal cancer in northern India. Ann Surg Oncol 2011; 18: 880-7.
65. Yang L, Zhu H, Zhou B, Gu H, Yan H, Tang N, et al. The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Dig Dis Sci 2009; 54: 1021-8.
66. Borges Bdo N, Burbano RR, Harada ML. Survivin -31C/G polymorphism and gastric cancer risk in a Brazilian population. Clin Exp Med 2011; 11: 189-93.
67. Kostić M, Nikolić N, Ilić B, Carkić J, Milenković S, Vukadinović M. Analysis of polymorphism in the survivin gene promoter as a potential risk factor for head and neck cancers development. Srp Arh Celok Lek 2013; 141: 304-7.
68. Farnebo L, Jerhammar F, Ceder R, Grafström RC, vainikka L, Thunell L, et al. Combining factors on protein and gene level to predict radioresponse in head and neck cancer cell lines. J Oral Pathol Med 2011; 40: 739-46.
69. Hsieh YS, Tsai CM, Yeh CB, Yang SF, Hsieh YH, Weng CJ. Survivin T9809C, an SNP located in 3'-UTR, displays a correlation with the risk and clinicopathological development of hepatocellular carcinoma. Ann Surg Oncol 2012; 19 (Suppl 3): S625-33.
70. Bayram S, Akkiz H, Bekar A, Akgöllü E. The association between the survivin -31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer Epidemiol 2011; 35: 555-9.
71. Lee JS, Kim JH, Park BL, Cheong HS, Kim JY, Park TJ, et al. Lack of Association of BIRC5 polymorphisms with clearance of HBv infection and HCC occurrence in a Korean population. Genomics Inform 2009; 7: 195-202.
72. Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH, et al. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 2008; 60: 31-9.
73. Dai J, Jin G, Dong J, Chen Y, Xu L, Hu Z, et al. Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival. J Thorac Oncol 2010; 5: 1748-54.
74. Krepela E, Dankova P, Moravcikova E, Krepelova A, Prochazka J, Cermak J, et al. Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. Int J Oncol 2009; 35: 1449-62.
75. weng CJ, Hsieh YH, Chen MK, Tsai CM, Lin CW, Yang SF. Survivin SNP-carcinogen interactions in oral cancer. J Dent Res 2012; 91: 358-63.
76. Qin C, Cao Q, Li P, Ju X, wang M, Chen J, et al. Functional promoter -31G>C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population. PLoS One 2012; 7: e28829.
77. Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003; 3: 17-22.
78. Sawyers C. Targeted cancer therapy. Nature 2004; 432: 294-7.
79. Reya T, Morrison SJ, Clarke MF, weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
80. Sakao S, Taraseviciene-Stewart L, Lee JD, wood K, Cool CD, voelkel NF. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J 2005; 19: 1178-80.
81. Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small- cell lung cancer. J Clin Oncol 2004; 22: 2808-15.
82. Tsuruma T, Hata F, Torigoe T, Furuhata T, Idenoue S, Kurotaki T, et al. Phase I clinical study of antiapoptosis protein, survivin- derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J TranslMed 2004; 2: 19.
83. Otto K, Andersen MH, Eggert A, Keikavoussi P, Pedersen LØ, Rath JC, et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 2005; 23: 884-9.
84. Groner B, weiss A. Targeting survivin in cancer: novel drug development approaches. BioDrugs 2014; 28: 27-39.
85. Kanwar JR, Kamalapuram SK, Kanwar RK. Survivin signaling in clinical oncology: a multifaceted dragon. Med Res Rev 2013; 33: 765-89.
86. Khan Z, Tiwari RP, Khan N, Prasad GB, Bisen PS. Induction of apoptosis and sensitization of head and neck squamous carcinoma cells to cisplatin by targeting survivin gene expression. Curr Gene Ther 2012; 12: 444-53.
87. Bisen PS, Khan Z, Bundela S. Biology of oral cancer key apoptotic regulators. Boca Ratan, FL, USA: CRC Press, Taylor and Francis Group; 2014. p. 272.
88. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009; 35: 553-62.
89. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin Ther Targets 2008; 12: 463-76.